KR20080110900A - 비장 티로신 키나아제-관련 염증 상태의 ＲＮＡｉ-매개성 억제 - Google Patents

비장 티로신 키나아제-관련 염증 상태의 ＲＮＡｉ-매개성 억제 Download PDF

Info

Publication number
KR20080110900A
KR20080110900A KR1020087027710A KR20087027710A KR20080110900A KR 20080110900 A KR20080110900 A KR 20080110900A KR 1020087027710 A KR1020087027710 A KR 1020087027710A KR 20087027710 A KR20087027710 A KR 20087027710A KR 20080110900 A KR20080110900 A KR 20080110900A
Authority
KR
South Korea
Prior art keywords
seq
interfering rna
nucleotides
syk
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087027710A
Other languages
English (en)
Korean (ko)
Inventor
존 엠. 예니
존 이. 채털튼
다니엘 에이. 가마치
스티븐 티. 밀러
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20080110900A publication Critical patent/KR20080110900A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087027710A 2006-04-13 2007-04-13 비장 티로신 키나아제-관련 염증 상태의 ＲＮＡｉ-매개성 억제 Ceased KR20080110900A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13
US60/791,847 2006-04-13

Publications (1)

Publication Number Publication Date
KR20080110900A true KR20080110900A (ko) 2008-12-19

Family

ID=38610402

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027710A Ceased KR20080110900A (ko) 2006-04-13 2007-04-13 비장 티로신 키나아제-관련 염증 상태의 ＲＮＡｉ-매개성 억제

Country Status (13)

Country Link
US (4) US8048863B2 (enExample)
EP (3) EP3156486A3 (enExample)
JP (1) JP2009533475A (enExample)
KR (1) KR20080110900A (enExample)
CN (2) CN101972483A (enExample)
AR (1) AR060448A1 (enExample)
AU (2) AU2007238027B2 (enExample)
BR (1) BRPI0709506A2 (enExample)
CA (1) CA2649138C (enExample)
MX (2) MX2008013068A (enExample)
TW (2) TW200808360A (enExample)
WO (1) WO2007121347A2 (enExample)
ZA (1) ZA200808744B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046059A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
US20110123637A1 (en) * 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
AU2009330458B2 (en) * 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
CN104805085A (zh) 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
SG11201705312PA (en) * 2014-12-29 2017-07-28 Bonac Corp Composition containing nucleic acid molecule stably
US10888391B2 (en) 2015-05-29 2021-01-12 Ablacon Inc Optical force sensing assembly for an elongated medical device
CA3002786C (en) 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
JPH11507824A (ja) * 1995-06-07 1999-07-13 ユニバーシティー・オブ・ペンシルバニア 食作用を阻害する方法
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
JP4649331B2 (ja) * 2002-10-01 2011-03-09 エピゲノミクス アーゲー 乳房細胞増殖障害の改良治療方法および核酸
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CN101914532A (zh) * 2002-11-22 2010-12-15 生物智囊团株式会社 Rna干扰的目标碱基序列的搜索方法
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP2371835A1 (en) * 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
CA2546074A1 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
EP1904649A2 (en) 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
TW200916117A (en) 2007-08-03 2009-04-16 Alcon Res Ltd RNAi-related inhibition of TNF α signaling pathway for treatment of ocular angiogenesis

Also Published As

Publication number Publication date
EP2662446A3 (en) 2014-04-02
CN101972483A (zh) 2011-02-16
BRPI0709506A2 (pt) 2011-07-19
CN101443020A (zh) 2009-05-27
WO2007121347A3 (en) 2008-12-04
EP3156486A2 (en) 2017-04-19
US20140357695A1 (en) 2014-12-04
US20110288157A1 (en) 2011-11-24
TW201336514A (zh) 2013-09-16
AU2007238027A1 (en) 2007-10-25
EP2004240A2 (en) 2008-12-24
ZA200808744B (en) 2009-12-30
CA2649138A1 (en) 2007-10-25
EP2004240A4 (en) 2010-12-15
US8865671B2 (en) 2014-10-21
AU2013207601B2 (en) 2016-11-17
AU2007238027B2 (en) 2013-08-15
MX2008013068A (es) 2008-12-16
MX345954B (es) 2017-02-16
US9371529B2 (en) 2016-06-21
US8048863B2 (en) 2011-11-01
CA2649138C (en) 2018-04-03
US20160257963A1 (en) 2016-09-08
TW200808360A (en) 2008-02-16
AR060448A1 (es) 2008-06-18
JP2009533475A (ja) 2009-09-17
EP2662446A2 (en) 2013-11-13
EP3156486A3 (en) 2017-07-12
US20090324507A1 (en) 2009-12-31
WO2007121347A2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
US7732421B2 (en) RNAI-mediated inhibition of tumor necrosis factor α-related conditions
US9371529B2 (en) RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US9745585B2 (en) RNAi-mediated inhibition of histamine receptor H1-related conditions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120409

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131202

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140716

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140716

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20131202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I